Marten Vos Email & Phone Number

Sydney, Nsw, Au

Melbourne, Victoria, Australia

Key member of the Medicines Development for Global Health CMC operations team, responsible for the development and implementation of CMC strategies for Medicines Development for Global Health products, spanning early development through to product registration.

Auckland, New Zealand

Providing CMC, Chemistry, Technical, Product and Process Development advice and expertise to Pharmaceutical (Human & Veterinary), Chemical, Nutraceutical, Dairy and Food Industries.

Auckland, New Zealand

Responsible for all R&D functions in this startup company focused on cannabis based therapeutics.Key Accomplishments:◾ First regulatory approval and launch of a New Zealand made cannabidiol product under the NZ Medicinal Cannabis Regulations 2019.◾ Implemented a Stage-Gate process to manage and prioritise the R&D portfolio.◾ Proposed to separate R&D from GMP operations to increase flexibility and productivity.◾ Proposed to establish regulatory and clinical teams to support product registrations with clinically proven label claims.

Auckland, New Zealand

Continuation of previous role with Bayer Animal Health upon completion of the sale to Elanco Animal Health. Responsible for all pharmaceutical development (CMC & Regulatory), product / technology transfers to manufacturing and lifecycle management activities of commercial product for the Asia Pacific region.Key Accomplishments:◾ Successful integration of the Bayer Animal Health APAC PD team into the new Elanco company structure.◾ Successful completion of the new APAC R&D laboratory and containment pilot plant on schedule and within budget despite the Covid-19 pandemic.◾ Multiple successful product transfers. ◾ Development of a novel controlled release anti-inflammatory product.

Auckland, New Zealand

Responsible for all pharmaceutical development (CMC & Regulatory), product / technology transfers to manufacturing and lifecycle management activities of commercial product for the Asia Pacific region. Hired to manage the transition of the Bayer Animal Health APAC Pharmaceutical Development team into the Elanco company structure as part of the sale to Elanco.Key Accomplishments:◾ Restructured the Bayer Animal Health APAC PD team to accommodate for the new post acquisition Elanco company structure.◾ Streamlined development operations to increase flexibility and increase output of the team.◾ Successful relocation of the Bayer APAC R&D laboratory to the new Elanco APAC R&D facility under construction.◾ Achieved continuity of BAU for products under development while relocating R&D facilities and preparing for new company ownership.

Auckland, New Zealand

Responsible for all pharmaceutical development (CMC development, regulatory support and technology transfer into manufacturing) at the NZ and USA sites. Managed a team of 36 research scientists responsible for technical development of an R&D project portfolio with a NPV> 200MM USD. Promoted from my previous role as Formulation Development Manager this role was created to consolidate formulation development and 2 analytical development teams under single leadership.Key accomplishments:◾ Integrated formulation, analytical and method development teams into one pharmaceutical development team.◾ CMC development of multiple products resulting in 14 ANDA approvals to date.◾ CMC development of multiple products resulting in 2 EU product approvals to date.◾ Oversaw multiple drug repurposing developments resulting in positive top-line results from Phase 2 trials for one of the molecules.◾ Provide CMC support to major development partnership with mid-sized US Pharma company as well as several other US Pharma companies.

Auckland, New Zealand

Responsible for all formulation development at the NZ site. Managed a team of 10 formulation scientists responsible for dosage form and process development. Was asked by senior management to return to pharmaceutical R&D to take up the role of Formulation Development Manager in order to support the CSO and R&D director in building an R&D project portfolio with a NPV> 200MM USD.Key Accomplishments:◾ Restructured and expanded the formulation development team.◾ Promoted to Pharmaceutical Development Manager.◾ 2 ANDA approvals.◾ Developed product formulations resulting in 12 ANDA applications.◾ Started several 505(b)2 product formulation developments to diversify the company R&D pipeline into more novel high value product developments.◾ Hired talented young scientists to increase team capabilities.◾ Provided support to the regulatory function to obtain product approvals.

Auckland, New Zealand

Responsible for all technical aspects and integration of the neutraceuticals business unit (Natural Health Laboratories Ltd) into the Douglas group in order to maintain regulatory compliance and provide technical support to sales, marketing and customers. Managed a team of 5 direct reports at head office in Auckland and a further 3 dotted line reports at the manufacturing facility in Fiji.Key Accomplishments:◾ Launch of the ‘Clinicians of NZ’ product range in Singapore pharmacies.◾ Regulatory approvals for 4 products for the Malaysian market.◾ Development of a selection of 25 Clinicians products suitable for ARTG listing with the Australian TGA. ◾ Implemented a quality framework more aligned with the pharma business in order to future proof nutraceutical manufacture and maintain compliance with regulatory changes proposed by the NZ authorities.◾ Introduced process validation to improve product quality and facilitate export.◾ Introduced stability programs to support shelf life claims and facilitate export.

Responsible for the technical aspects of new product development. Managed a small team of analytical and formulation scientists developing drug products and preparing CMC documentation to support regulatory submissions.Key Accomplishments:◾ First ANDA approval for Douglas by the US FDA.◾ EU approval for a line extension to a major Douglas export product.◾ First NDA approval for Douglas by the US FDA◾ First person in R&D to write a business case and present this to senior management as part of the implementation of a Stage-Gate process to manage new product developments.

Groningen, Netherlands

Responsible for kilogram laboratory operations and scale up of synthetic organic chemistry routes for custom synthesis of complex novel molecules. Managed a team of four synthetic organic chemists (MSc / PhD) specialized in scale up from mg to kg quantities and redesign of synthetic routes to facilitate scale up of the synthesis of novel lead structures, pharmaceutical reference compounds and preclinical drug development. Reported to the CEO. Key Accomplishments:◾ Actively involved in design and construction of new 27,000 sq ft building including pilot plant facilties to double company footprint.◾ Increased pilot plant capabilities with acquisition of first 50 L multipurpose reactor.◾ Recruitment of new staff to accommodate company growth (15-30% per annum from 2000 to 2006).◾ Trained staff in process development and scale up operations. ◾ 60 completed projects.◾ 270 molecules synthesized.

Groningen, Netherlands

Responsible for synthesis, route scouting and scale up of fine chemicals up to kilogram scale. Supervised two research chemists and oversaw general laboratory operations and maintenance. Reported to the founder.Key Accomplishments:◾ Promoted (6 months after hire) to supervise staff and oversee laboratory operations. ◾ Trained staff in scale up operations. ◾ Obtained considerable expertise in applied synthetic organic chemistry.◾ Specialized in route design and process development for scale up.

Groningen, Netherlands

Employed within the Positron Emission Tomography (PET) group of the department of Nuclear Medicine on a 2 year grant from the Dutch Digestive Foundation. The primary objective was to synthesize radioactively labelled molecules for imaging of tissue regeneration after liver transplants and automate the process the facilitate routine production.Key Accomplishments:◾ Developed and optimized of the synthesis of [11C]-labelled thymidine. ◾ Developed and constructed a PLC controlled system for synthesis of [11C]-labelled thymidine.◾ Developed and synthesized [18F]-labelled derivatives of thymidine as alternatives for [11C]-labelling and possible labelling of “antisense” nucleotides.◾ Research results presented during the Eleventh International Symposium on Radiopharmaceutical Chemistry (August 1995, Vancouver, Canada).

Groningen, Netherlands

Research period within the Positron Emission Tomography (PET) group (supervisors Professor P.H. Elsinga Ph.D. and G.M. Visser Ph.D.) of the department of Nuclear Medicine. The primary objective was the synthesis and in vivo evaluation of radioactively labelled [18F]-fluorocarazolol a ligand for the visualisation of pulmonary beta-adrenergic receptors with Positron Emission Tomography (PET).Key Accomplishments:◾ Granted an Engineers Degree in chemistry◾ Developed an improved stereo selective synthesis of fluorocarazolol.◾ Synthesis and in vivo evaluation of radioactively labelled [18F]-fluorocarazolol. ◾ Research results presented during the Tenth International Symposium on Radiopharmaceutical Chemistry (October 1993, Kyoto, Japan).◾ PET imaging results of pulmonary beta-adrenoceptors presented during the 41st annual meeting of the Society of Nuclear Medicine (June 1994 Orlando, Fl, USA).◾ Full paper: Nucl. Med. Biol. 1996 23 159-167.

Postgraduate Courses

Engineer'S Degree

Education record